Eli Lilly and Company, a global pharmaceutical leader, has significantly bolstered its commitment to the cutting-edge field of genetic medicines…
Read More
Eli Lilly and Ascidian Therapeutics Forge Strategic Alliance to Revolutionize Kidney Disease Treatment Through Advanced Genetic Medicine
Eli Lilly and Company has announced a significant research collaboration and licensing agreement with Ascidian Therapeutics, a pioneering biotechnology firm…
Read More
ASCO 2026: Navigating the Evolving Landscape of Non-Small Cell Lung Cancer with Promising Data from Eli Lilly and Mixed Reactions for Summit/Akeso
The American Society of Clinical Oncology (ASCO) 2026, held from May 29 to June 2, 2026, served as a critical…
Read More
Lilly’s $7bn Acquisition of Kelonia Bears Fruit as In Vivo Cell Therapies Show Significant Promise at ASCO 2026
The American Society for Clinical Oncology (ASCO) meeting in 2026, a cornerstone event for oncological advancements, has concluded, leaving behind…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
A transformative partnership has been forged between Insilico Medicine, a pioneer in artificial intelligence-driven drug discovery, and Eli Lilly, a…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company is embarking on a significant acquisition spree, exemplified by its recent agreement to acquire Kelonia Therapeutics…
Read More
Eli Lilly and Company Secures Global Rights to Hanmi Pharm’s Sonefpeglutide in Potential $1.26 Billion Deal
Eli Lilly and Company has forged a significant licensing agreement with South Korean biopharmaceutical firm Hanmi Pharm, potentially worth up…
Read More
Eli Lilly’s Retatrutide Demonstrates Unprecedented Weight Loss with Notable Side Effect Profile in Phase 3 Trials
Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…
Read More
Insilico Medicine and Eli Lilly Forge Potentially $2.75 Billion AI-Driven Drug Discovery Alliance, Signaling a New Era of Pharmaceutical Innovation
On March 29, Insilico Medicine, a pioneering company in artificial intelligence-driven drug discovery and development, announced a landmark collaboration with…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently riding an unprecedented wave of success fueled by its GLP-1 franchise, has announced its intent…
Read More
